Project Grant K99CA296996
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$163K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), will fund a longitudinal study on the mechanisms of radiation-induced neurocognitive decline in patients with glioma. The $667,485 award to the University of California, San Diego (UCSD) aims to:
Characterize neurocognitive heterogeneity and identify cognitive phenotypes in glioma patients before and after radiation therapy (RT).
Analyze...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research federal grant program (CFDA 93.395), provides $607,580 to The Regents of the University of California, San Francisco (UCSF) to advance cancer research. The key objectives are to: 1) identify molecular markers that distinguish tumor vasculature from normal vasculature, 2) determine if inhibition of the marker ENPEP promotes favorable outcomes in glioblastoma (GBM) mouse models, and 3) develop...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) in the amount of $1,243,002 will fund research aimed at improving survival rates for children with diffuse midline gliomas (DMG), a type of malignant brain tumor. The grant recipient, Dana-Farber Cancer Institute, will collaborate with researchers at the University of California, San Francisco to test the hypothesis that combining radiation therapy with drugs targeting DNA replication...
This $389,988 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports research on the role of tRNA modifications in regulating cancer stem cell (CSC) biology in glioblastoma (GBM). The University of Pittsburgh, the prime awardee, will use mass spectrometry and ribosome profiling techniques to study how altered tRNA modification patterns impact translational reprogramming and drive oncogenic processes in GBM CSCs. The...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $686,979.00 in funding to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at understanding and disrupting tumor metabolism and enhancing anti-tumor immunity in diffuse midline gliomas (DMGs), a type of aggressive pediatric brain cancer. The key goals are to: 1) Delineate how the H3K27M mutation in DMGs upregulates the glycolytic enzyme PGK1...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to SRI International provides $401,125 in funding to quantify the association between genetic factors and radiation sensitivity in cancer patients. The research aims to identify germline genetic variants and gene expression patterns that contribute to individual differences in radiation response. The goal is to develop a predictive screening platform to optimize radiation dosing and mitigate...
This $655,306 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to validate a novel therapeutic approach for treating gliomas, a deadly form of brain cancer. The grant supports research to determine if inhibiting the enzyme glyoxalase 1 (GLO1) in combination with radiation therapy is an effective strategy for treating gliomas with mutations in the isocitrate dehydrogenase 1 or 2 (IDHm) genes. The project will leverage...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $249,000.00 to the Trustees of the University of Pennsylvania to conduct research aimed at decoding the evolution and progression of glioma, an incurable brain cancer. The research plan involves developing novel single-cell technologies to concurrently profile the transcriptome, epigenome, and genome of glioma cells. This multi-dimensional profiling will help define how...
This $676,567 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Regents of the University of California, San Francisco (UCSF). The grant supports a 5-year research project to systematically evaluate the effectiveness of a transforming growth factor beta (TGFβ)-targeted radiopharmaceutical therapy (RPT) as a potential tumor-agnostic cancer treatment. The project aims to radiolabel a validated TGFβ-neutralizing...
This $634,743 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting the development of novel nanotherapeutics to overcome therapy resistance in high-grade gliomas, a fatal type of brain tumor. The award recipient, the University of California, Davis, is leveraging expertise in generating BBB/BBTB-traversing and tumor-penetrating nanoparticles loaded with potent autophagy-inhibiting bisaminoquinoline derivatives and the cytotoxic...